| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Janus Kinase 2 | 24 | 2022 | 36 | 5.720 |
Why?
|
| Protein Tyrosine Phosphatases | 13 | 2014 | 37 | 2.480 |
Why?
|
| Polycythemia Vera | 10 | 2020 | 14 | 2.390 |
Why?
|
| Myeloproliferative Disorders | 10 | 2022 | 11 | 1.850 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2022 | 32 | 1.840 |
Why?
|
| Mutation, Missense | 4 | 2014 | 67 | 1.320 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2022 | 142 | 1.290 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 8 | 2016 | 19 | 1.190 |
Why?
|
| Point Mutation | 4 | 2014 | 60 | 1.050 |
Why?
|
| Primary Myelofibrosis | 6 | 2022 | 9 | 0.970 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2012 | 95 | 0.940 |
Why?
|
| Mast Cells | 2 | 2014 | 9 | 0.940 |
Why?
|
| Mutation | 11 | 2020 | 814 | 0.910 |
Why?
|
| Caenorhabditis elegans | 4 | 2014 | 58 | 0.900 |
Why?
|
| Phosphorylation | 16 | 2023 | 557 | 0.900 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 5 | 2020 | 13 | 0.900 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2021 | 5 | 0.890 |
Why?
|
| Mice | 30 | 2023 | 4389 | 0.880 |
Why?
|
| Cell Line, Tumor | 13 | 2023 | 1254 | 0.870 |
Why?
|
| Animals | 39 | 2023 | 9918 | 0.870 |
Why?
|
| Signal Transduction | 14 | 2021 | 1332 | 0.840 |
Why?
|
| Caenorhabditis elegans Proteins | 3 | 2014 | 55 | 0.830 |
Why?
|
| Thrombopoietin | 2 | 2020 | 17 | 0.780 |
Why?
|
| Amino Acid Substitution | 7 | 2019 | 102 | 0.780 |
Why?
|
| Tyrosine | 8 | 2023 | 90 | 0.770 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2012 | 228 | 0.750 |
Why?
|
| Carcinogenesis | 2 | 2023 | 79 | 0.740 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 14 | 0.700 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2020 | 16 | 0.690 |
Why?
|
| Humans | 51 | 2023 | 26741 | 0.690 |
Why?
|
| Mice, Transgenic | 11 | 2020 | 487 | 0.690 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 9 | 2014 | 276 | 0.680 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 338 | 0.660 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2020 | 139 | 0.640 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 131 | 0.620 |
Why?
|
| Polymerase Chain Reaction | 6 | 2012 | 262 | 0.620 |
Why?
|
| Autophagy | 3 | 2016 | 69 | 0.620 |
Why?
|
| Cell Proliferation | 9 | 2022 | 761 | 0.620 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2014 | 6 | 0.590 |
Why?
|
| Mice, Inbred C57BL | 11 | 2020 | 1468 | 0.590 |
Why?
|
| Enzyme Inhibitors | 5 | 2012 | 247 | 0.570 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2021 | 14 | 0.560 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2021 | 662 | 0.550 |
Why?
|
| Molecular Sequence Data | 9 | 2014 | 1034 | 0.520 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 122 | 0.500 |
Why?
|
| Choanoflagellata | 1 | 2014 | 1 | 0.490 |
Why?
|
| Pruritus | 1 | 2014 | 8 | 0.470 |
Why?
|
| Cardiomegaly | 1 | 2014 | 18 | 0.470 |
Why?
|
| Chymases | 1 | 2013 | 2 | 0.460 |
Why?
|
| Mice, Congenic | 1 | 2013 | 3 | 0.460 |
Why?
|
| Amino Acid Sequence | 7 | 2014 | 673 | 0.460 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 17 | 0.460 |
Why?
|
| Models, Animal | 1 | 2013 | 128 | 0.440 |
Why?
|
| Apoptosis | 6 | 2021 | 736 | 0.420 |
Why?
|
| Pyrroles | 1 | 2012 | 35 | 0.420 |
Why?
|
| Muscles | 1 | 2012 | 70 | 0.410 |
Why?
|
| Substrate Specificity | 6 | 2014 | 149 | 0.400 |
Why?
|
| Quinazolines | 2 | 2014 | 31 | 0.400 |
Why?
|
| Membrane Proteins | 4 | 2021 | 466 | 0.400 |
Why?
|
| Indoles | 1 | 2012 | 97 | 0.400 |
Why?
|
| Camellia sinensis | 1 | 2011 | 3 | 0.380 |
Why?
|
| Tea | 1 | 2011 | 7 | 0.380 |
Why?
|
| Hematologic Diseases | 1 | 2011 | 10 | 0.370 |
Why?
|
| Peptide Fragments | 1 | 2012 | 196 | 0.370 |
Why?
|
| Cloning, Molecular | 5 | 2014 | 204 | 0.370 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2011 | 23 | 0.370 |
Why?
|
| Ethanol | 1 | 2011 | 117 | 0.360 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 651 | 0.360 |
Why?
|
| Longevity | 1 | 2011 | 129 | 0.350 |
Why?
|
| Receptors, Thrombopoietin | 2 | 2020 | 8 | 0.320 |
Why?
|
| Erythropoiesis | 3 | 2014 | 9 | 0.320 |
Why?
|
| Stilbenes | 4 | 2014 | 90 | 0.320 |
Why?
|
| Blotting, Western | 5 | 2014 | 503 | 0.320 |
Why?
|
| Gene Frequency | 2 | 2021 | 182 | 0.310 |
Why?
|
| Transgenes | 1 | 2008 | 59 | 0.300 |
Why?
|
| Clinical Enzyme Tests | 1 | 2007 | 3 | 0.300 |
Why?
|
| Base Sequence | 8 | 2012 | 573 | 0.290 |
Why?
|
| Enzyme Activation | 6 | 2014 | 262 | 0.290 |
Why?
|
| Alleles | 3 | 2021 | 347 | 0.290 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 11 | 0.280 |
Why?
|
| Breast Neoplasms | 4 | 2016 | 440 | 0.280 |
Why?
|
| Protein Structure, Tertiary | 5 | 2012 | 283 | 0.270 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 23 | 0.270 |
Why?
|
| Jurkat Cells | 4 | 2014 | 29 | 0.270 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 6 | 2011 | 13 | 0.260 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2017 | 58 | 0.260 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2005 | 48 | 0.250 |
Why?
|
| Bone Marrow | 4 | 2017 | 76 | 0.250 |
Why?
|
| Phenotype | 3 | 2020 | 661 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 438 | 0.250 |
Why?
|
| Receptors, Immunologic | 2 | 2002 | 64 | 0.250 |
Why?
|
| Cells, Cultured | 6 | 2020 | 967 | 0.240 |
Why?
|
| Macrophages | 2 | 2020 | 272 | 0.240 |
Why?
|
| Male | 10 | 2020 | 12817 | 0.240 |
Why?
|
| MicroRNAs | 2 | 2020 | 278 | 0.240 |
Why?
|
| Bone Marrow Cells | 3 | 2014 | 79 | 0.230 |
Why?
|
| Glutathione Transferase | 3 | 2012 | 29 | 0.230 |
Why?
|
| Biological Assay | 2 | 2016 | 35 | 0.230 |
Why?
|
| Erythroid Precursor Cells | 1 | 2003 | 1 | 0.230 |
Why?
|
| Phosphatidylserines | 1 | 2003 | 20 | 0.220 |
Why?
|
| Recombinant Proteins | 4 | 2021 | 407 | 0.210 |
Why?
|
| Cell Adhesion | 1 | 2023 | 132 | 0.210 |
Why?
|
| Phospholipids | 1 | 2003 | 73 | 0.210 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2020 | 36 | 0.210 |
Why?
|
| Phosphoproteins | 1 | 2003 | 115 | 0.210 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2022 | 11 | 0.210 |
Why?
|
| Cell Line | 6 | 2006 | 671 | 0.210 |
Why?
|
| GATA2 Transcription Factor | 1 | 2022 | 3 | 0.210 |
Why?
|
| HMGA1a Protein | 1 | 2022 | 4 | 0.210 |
Why?
|
| Small Molecule Libraries | 2 | 2012 | 17 | 0.200 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2012 | 56 | 0.200 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 482 | 0.200 |
Why?
|
| RNA, Small Interfering | 3 | 2019 | 194 | 0.200 |
Why?
|
| Alternative Splicing | 3 | 2010 | 44 | 0.200 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 1391 | 0.190 |
Why?
|
| Cell Movement | 1 | 2023 | 352 | 0.190 |
Why?
|
| Carrier Proteins | 1 | 2003 | 244 | 0.190 |
Why?
|
| Valine | 4 | 2014 | 12 | 0.190 |
Why?
|
| Mycobacterium leprae | 1 | 2021 | 2 | 0.190 |
Why?
|
| Leprosy | 1 | 2021 | 4 | 0.190 |
Why?
|
| Phenylalanine | 4 | 2014 | 23 | 0.190 |
Why?
|
| Maytansine | 1 | 2021 | 4 | 0.190 |
Why?
|
| Quinolines | 2 | 2020 | 25 | 0.190 |
Why?
|
| Tuberculosis | 1 | 2021 | 23 | 0.190 |
Why?
|
| Female | 11 | 2016 | 14402 | 0.180 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2021 | 28 | 0.180 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2020 | 17 | 0.180 |
Why?
|
| Thrombocythemia, Essential | 1 | 2020 | 1 | 0.180 |
Why?
|
| Oxidative Stress | 2 | 2023 | 618 | 0.180 |
Why?
|
| Cell Death | 1 | 2020 | 110 | 0.180 |
Why?
|
| Pyrazoles | 2 | 2020 | 62 | 0.180 |
Why?
|
| RNA Interference | 2 | 2012 | 135 | 0.180 |
Why?
|
| HCT116 Cells | 1 | 2020 | 53 | 0.180 |
Why?
|
| Sensitivity and Specificity | 4 | 2011 | 509 | 0.180 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2020 | 1 | 0.180 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2020 | 1 | 0.180 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2020 | 7 | 0.180 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 245 | 0.180 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2020 | 18 | 0.170 |
Why?
|
| Janus Kinases | 3 | 2023 | 5 | 0.170 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2019 | 5 | 0.170 |
Why?
|
| Caspases | 1 | 2019 | 42 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2014 | 83 | 0.170 |
Why?
|
| Proteins | 1 | 2002 | 244 | 0.170 |
Why?
|
| Mitochondrial Proteins | 1 | 2020 | 70 | 0.170 |
Why?
|
| Spleen | 3 | 2014 | 109 | 0.170 |
Why?
|
| Epistasis, Genetic | 1 | 2019 | 24 | 0.160 |
Why?
|
| Protein Isoforms | 3 | 2010 | 117 | 0.160 |
Why?
|
| Amino Acid Motifs | 3 | 2003 | 66 | 0.160 |
Why?
|
| Tomography | 1 | 2018 | 17 | 0.160 |
Why?
|
| Photoacoustic Techniques | 1 | 2018 | 17 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 542 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 143 | 0.150 |
Why?
|
| Sequence Alignment | 3 | 2010 | 110 | 0.150 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2018 | 20 | 0.150 |
Why?
|
| Nanomedicine | 1 | 2018 | 62 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2019 | 114 | 0.150 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 128 | 0.150 |
Why?
|
| Protein Binding | 3 | 2006 | 631 | 0.150 |
Why?
|
| NIH 3T3 Cells | 2 | 2011 | 44 | 0.150 |
Why?
|
| DNA Primers | 3 | 2013 | 143 | 0.150 |
Why?
|
| src Homology Domains | 3 | 2011 | 31 | 0.140 |
Why?
|
| Erythropoietin | 2 | 2008 | 12 | 0.140 |
Why?
|
| Neurites | 1 | 2016 | 9 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 2 | 2020 | 86 | 0.140 |
Why?
|
| Receptor, trkA | 1 | 2016 | 9 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 1924 | 0.140 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 60 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 437 | 0.130 |
Why?
|
| Time Factors | 2 | 2014 | 1564 | 0.130 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 981 | 0.130 |
Why?
|
| Escherichia coli | 3 | 2022 | 328 | 0.130 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 624 | 0.120 |
Why?
|
| Mice, Knockout | 3 | 2014 | 779 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2006 | 23 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 2 | 2012 | 310 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2006 | 160 | 0.120 |
Why?
|
| Exosomes | 1 | 2016 | 86 | 0.120 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 2014 | 3 | 0.120 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 54 | 0.120 |
Why?
|
| Genes, p53 | 1 | 2014 | 14 | 0.120 |
Why?
|
| Interleukin-3 | 1 | 2014 | 3 | 0.120 |
Why?
|
| Crosses, Genetic | 1 | 2014 | 36 | 0.120 |
Why?
|
| Stem Cell Factor | 1 | 2014 | 5 | 0.120 |
Why?
|
| Cricetulus | 1 | 2014 | 56 | 0.120 |
Why?
|
| Species Specificity | 1 | 2014 | 185 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 101 | 0.120 |
Why?
|
| CHO Cells | 1 | 2014 | 96 | 0.120 |
Why?
|
| Neoplasms | 1 | 2023 | 748 | 0.120 |
Why?
|
| Cricetinae | 1 | 2014 | 129 | 0.120 |
Why?
|
| Serine Endopeptidases | 1 | 2013 | 18 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 110 | 0.110 |
Why?
|
| Aged | 4 | 2016 | 5152 | 0.110 |
Why?
|
| Fibrosis | 1 | 2014 | 115 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 129 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 375 | 0.110 |
Why?
|
| Liver | 2 | 2014 | 414 | 0.110 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2013 | 3 | 0.110 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 1 | 1 | 2013 | 1 | 0.110 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2013 | 9 | 0.110 |
Why?
|
| Stem Cells | 1 | 2014 | 113 | 0.110 |
Why?
|
| Protein Transport | 2 | 2016 | 152 | 0.110 |
Why?
|
| Skin | 1 | 2014 | 139 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2013 | 18 | 0.110 |
Why?
|
| Oncogene Proteins | 1 | 2013 | 21 | 0.110 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 18 | 0.110 |
Why?
|
| SH2 Domain-Containing Protein Tyrosine Phosphatases | 2 | 2003 | 2 | 0.110 |
Why?
|
| Protein Kinases | 2 | 2020 | 143 | 0.110 |
Why?
|
| Immunoglobulins | 2 | 2003 | 33 | 0.110 |
Why?
|
| Body Size | 1 | 2012 | 30 | 0.110 |
Why?
|
| Limb Deformities, Congenital | 1 | 2012 | 3 | 0.100 |
Why?
|
| Scalp Dermatoses | 1 | 2012 | 4 | 0.100 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2012 | 6 | 0.100 |
Why?
|
| Ectodermal Dysplasia | 1 | 2012 | 6 | 0.100 |
Why?
|
| Tissue Distribution | 2 | 2003 | 132 | 0.100 |
Why?
|
| Hyperplasia | 2 | 2012 | 27 | 0.100 |
Why?
|
| Peptides | 1 | 2014 | 279 | 0.100 |
Why?
|
| Middle Aged | 4 | 2016 | 6790 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2013 | 90 | 0.100 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2014 | 10 | 0.100 |
Why?
|
| HeLa Cells | 2 | 2020 | 206 | 0.100 |
Why?
|
| Proteomics | 1 | 2013 | 177 | 0.100 |
Why?
|
| Homeostasis | 1 | 2013 | 113 | 0.100 |
Why?
|
| Models, Molecular | 2 | 2011 | 440 | 0.100 |
Why?
|
| Benzylamines | 1 | 2011 | 19 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 90 | 0.100 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 2 | 0.100 |
Why?
|
| Thiophenes | 1 | 2011 | 14 | 0.100 |
Why?
|
| Aconitate Hydratase | 1 | 2011 | 4 | 0.100 |
Why?
|
| Chemotactic Factors | 1 | 2011 | 7 | 0.100 |
Why?
|
| Cytosol | 2 | 2019 | 47 | 0.100 |
Why?
|
| Monophenol Monooxygenase | 1 | 2011 | 5 | 0.100 |
Why?
|
| Catechin | 1 | 2011 | 13 | 0.090 |
Why?
|
| Eating | 1 | 2011 | 66 | 0.090 |
Why?
|
| Amniotic Fluid | 1 | 2011 | 5 | 0.090 |
Why?
|
| Chromatography, Reverse-Phase | 1 | 2011 | 9 | 0.090 |
Why?
|
| Reproduction | 1 | 2011 | 63 | 0.090 |
Why?
|
| Models, Chemical | 1 | 2011 | 88 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 114 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 93 | 0.090 |
Why?
|
| Cytokines | 2 | 2020 | 437 | 0.090 |
Why?
|
| Adult | 4 | 2014 | 7350 | 0.090 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 32 | 0.090 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 352 | 0.090 |
Why?
|
| DNA | 1 | 2011 | 364 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2010 | 96 | 0.090 |
Why?
|
| Insulin | 1 | 2011 | 309 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2023 | 644 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 49 | 0.080 |
Why?
|
| Genotype | 3 | 2021 | 441 | 0.080 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 110 | 0.080 |
Why?
|
| Cell Communication | 1 | 2009 | 66 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 290 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 2 | 2013 | 364 | 0.080 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 2008 | 11 | 0.080 |
Why?
|
| Locomotion | 1 | 2008 | 22 | 0.080 |
Why?
|
| Cell Division | 2 | 2010 | 153 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2005 | 130 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2008 | 277 | 0.070 |
Why?
|
| Binding Sites | 2 | 2011 | 338 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2012 | 263 | 0.070 |
Why?
|
| Structure-Activity Relationship | 3 | 2011 | 200 | 0.070 |
Why?
|
| Diagnosis-Related Groups | 1 | 2006 | 10 | 0.070 |
Why?
|
| Sampling Studies | 1 | 2006 | 23 | 0.070 |
Why?
|
| Blood Cell Count | 1 | 2006 | 15 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 45 | 0.070 |
Why?
|
| Mitochondria | 2 | 2020 | 324 | 0.070 |
Why?
|
| China | 1 | 2006 | 53 | 0.070 |
Why?
|
| Caco-2 Cells | 1 | 2006 | 5 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2006 | 38 | 0.070 |
Why?
|
| Gene Knockout Techniques | 2 | 2019 | 35 | 0.070 |
Why?
|
| Models, Biological | 2 | 2012 | 446 | 0.070 |
Why?
|
| Inpatients | 1 | 2006 | 56 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2006 | 74 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2005 | 11 | 0.070 |
Why?
|
| Rats | 2 | 2016 | 1535 | 0.070 |
Why?
|
| Embryonic Development | 1 | 2005 | 21 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 145 | 0.060 |
Why?
|
| Phospholipase D | 1 | 2005 | 1 | 0.060 |
Why?
|
| Platelet Activation | 1 | 2005 | 54 | 0.060 |
Why?
|
| Cell Survival | 2 | 2021 | 392 | 0.060 |
Why?
|
| Oncogene Protein pp60(v-src) | 1 | 2005 | 6 | 0.060 |
Why?
|
| Receptors, Erythropoietin | 1 | 2005 | 3 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2005 | 76 | 0.060 |
Why?
|
| Heterozygote | 1 | 2005 | 64 | 0.060 |
Why?
|
| Kinetics | 2 | 2003 | 538 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 203 | 0.060 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2020 | 31 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2005 | 121 | 0.060 |
Why?
|
| Megakaryocytes | 2 | 2017 | 29 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 216 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2017 | 171 | 0.060 |
Why?
|
| Transfection | 1 | 2005 | 312 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2006 | 857 | 0.060 |
Why?
|
| Colony-Forming Units Assay | 1 | 2003 | 8 | 0.060 |
Why?
|
| Enzyme Induction | 1 | 2003 | 27 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2003 | 22 | 0.060 |
Why?
|
| Gene Targeting | 1 | 2003 | 16 | 0.060 |
Why?
|
| Genes, Dominant | 1 | 2003 | 35 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 109 | 0.060 |
Why?
|
| Gene Components | 1 | 2003 | 2 | 0.060 |
Why?
|
| RNA Splice Sites | 1 | 2003 | 5 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2003 | 65 | 0.050 |
Why?
|
| Biomarkers | 1 | 2006 | 729 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 130 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2003 | 98 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2022 | 10 | 0.050 |
Why?
|
| Sepharose | 1 | 2022 | 14 | 0.050 |
Why?
|
| Imatinib Mesylate | 1 | 2022 | 11 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2002 | 26 | 0.050 |
Why?
|
| Kidney | 1 | 2004 | 274 | 0.050 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2002 | 4 | 0.050 |
Why?
|
| Vanadates | 1 | 2002 | 2 | 0.050 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2002 | 2 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 21 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2017 | 394 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2022 | 75 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2002 | 81 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2003 | 235 | 0.050 |
Why?
|
| Computational Biology | 1 | 2023 | 150 | 0.050 |
Why?
|
| Chromatin | 1 | 2022 | 73 | 0.050 |
Why?
|
| Publication Bias | 1 | 2021 | 11 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2002 | 95 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 144 | 0.050 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2021 | 30 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 332 | 0.050 |
Why?
|
| DNA, Z-Form | 1 | 2020 | 2 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2020 | 5 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2020 | 19 | 0.050 |
Why?
|
| RAW 264.7 Cells | 1 | 2020 | 21 | 0.050 |
Why?
|
| Macrophage Activation | 1 | 2020 | 32 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 142 | 0.050 |
Why?
|
| Risk | 1 | 2021 | 133 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2021 | 231 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 82 | 0.040 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 1 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 8 | 0.040 |
Why?
|
| Cattle | 1 | 2002 | 383 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2021 | 109 | 0.040 |
Why?
|
| Nitriles | 1 | 2020 | 32 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 2020 | 19 | 0.040 |
Why?
|
| Cycloheximide | 1 | 2019 | 10 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2014 | 511 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 239 | 0.040 |
Why?
|
| Histones | 1 | 2020 | 90 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 131 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 43 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 67 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 120 | 0.040 |
Why?
|
| Malaria | 1 | 2018 | 15 | 0.040 |
Why?
|
| Transcriptome | 1 | 2020 | 198 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 244 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2018 | 84 | 0.040 |
Why?
|
| Exome | 1 | 2018 | 30 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 96 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2018 | 47 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2018 | 59 | 0.040 |
Why?
|
| Smad3 Protein | 1 | 2017 | 10 | 0.040 |
Why?
|
| Crystallography, X-Ray | 2 | 2011 | 214 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 450 | 0.040 |
Why?
|
| PC12 Cells | 1 | 2016 | 20 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2018 | 229 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2016 | 31 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 62 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 758 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 104 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 322 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 594 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 137 | 0.030 |
Why?
|
| Collagen | 1 | 2017 | 147 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 456 | 0.030 |
Why?
|
| Genes, Essential | 1 | 2014 | 2 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 221 | 0.030 |
Why?
|
| Heat-Shock Response | 1 | 2014 | 12 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 698 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 34 | 0.030 |
Why?
|
| United States | 1 | 2020 | 2025 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 66 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2014 | 158 | 0.030 |
Why?
|
| Erythroblasts | 1 | 2013 | 3 | 0.030 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2013 | 10 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2013 | 45 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 20 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 2013 | 33 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 88 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2014 | 282 | 0.030 |
Why?
|
| Anemia, Hemolytic | 1 | 2013 | 22 | 0.030 |
Why?
|
| Anemia | 1 | 2013 | 41 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2013 | 61 | 0.030 |
Why?
|
| Transcription Factor HES-1 | 1 | 2012 | 6 | 0.030 |
Why?
|
| Reticulin | 1 | 2012 | 1 | 0.030 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2012 | 3 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2012 | 6 | 0.030 |
Why?
|
| Splenomegaly | 1 | 2012 | 10 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 27 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2012 | 50 | 0.030 |
Why?
|
| Risk Factors | 1 | 2018 | 2008 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 58 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2012 | 27 | 0.030 |
Why?
|
| Pedigree | 1 | 2012 | 151 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2012 | 43 | 0.030 |
Why?
|
| Hydroxylation | 1 | 2011 | 9 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 47 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 74 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2011 | 22 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2011 | 30 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 308 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 155 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 246 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2011 | 239 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 587 | 0.020 |
Why?
|
| Tumor Protein p73 | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cell Count | 1 | 2009 | 84 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 180 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2014 | 2262 | 0.020 |
Why?
|
| Transition Temperature | 1 | 2007 | 6 | 0.020 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2006 | 6 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2006 | 18 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2006 | 48 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 31 | 0.020 |
Why?
|
| Protein Phosphatase 1 | 1 | 2006 | 5 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2006 | 13 | 0.020 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2006 | 18 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2006 | 65 | 0.020 |
Why?
|
| Bone Development | 1 | 2005 | 6 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 138 | 0.020 |
Why?
|
| Secretory Vesicles | 1 | 2005 | 11 | 0.020 |
Why?
|
| Cerebral Infarction | 1 | 2005 | 26 | 0.020 |
Why?
|
| Neural Tube Defects | 1 | 2005 | 19 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 196 | 0.020 |
Why?
|
| Palmitic Acids | 1 | 2005 | 1 | 0.020 |
Why?
|
| COS Cells | 1 | 2005 | 48 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 67 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2005 | 67 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 123 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 272 | 0.010 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2004 | 26 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2005 | 259 | 0.010 |
Why?
|
| Fetus | 1 | 2004 | 76 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2005 | 203 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 453 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 2002 | 130 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 398 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2002 | 250 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2002 | 77 | 0.010 |
Why?
|